Representing Patients Suffering Side Effects From ACTOS

In June 2011, the Food and Drug Administration (“FDA”) officially linked the popular Type II diabetes drug Actos to an increased risk of bladder cancer. The FDA concluded that compared to those who never took the drug, people who had been prescribed it for at least 12 months were 40% more likely to develop bladder cancer.

The sale of Actos has since been suspended in France and Germany, and new warnings have been added to labels in the United States. The FDA is still looking into the matter.

If you or a loved one has taken Actos and have since been diagnosed with bladder cancer, you may be entitled to compensatory damages. Call or email us today to review your case.